ARS PHARMACEUTICALS INC (SPRY) Fundamental Analysis & Valuation

NASDAQ:SPRY • US82835W1080

Current stock price

8.17 USD
-0.08 (-0.97%)
At close:
8.17 USD
0 (0%)
After Hours:

This SPRY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SPRY Profitability Analysis

1.1 Basic Checks

  • In the past year SPRY has reported negative net income.
  • In the past year SPRY has reported a negative cash flow from operations.
  • SPRY had negative earnings in 4 of the past 5 years.
  • SPRY had negative operating cash flow in 4 of the past 5 years.
SPRY Yearly Net Income VS EBIT VS OCF VS FCFSPRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • SPRY has a Return On Assets of -52.28%. This is comparable to the rest of the industry: SPRY outperforms 47.00% of its industry peers.
  • The Return On Equity of SPRY (-149.92%) is worse than 63.64% of its industry peers.
Industry RankSector Rank
ROA -52.28%
ROE -149.92%
ROIC N/A
ROA(3y)-24.44%
ROA(5y)-22.49%
ROE(3y)-56.79%
ROE(5y)-42.32%
ROIC(3y)N/A
ROIC(5y)N/A
SPRY Yearly ROA, ROE, ROICSPRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • Looking at the Gross Margin, with a value of 75.77%, SPRY belongs to the top of the industry, outperforming 83.75% of the companies in the same industry.
  • SPRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRY Yearly Profit, Operating, Gross MarginsSPRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SPRY Health Analysis

2.1 Basic Checks

  • SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SPRY has more shares outstanding
  • The number of shares outstanding for SPRY has been increased compared to 5 years ago.
  • Compared to 1 year ago, SPRY has a worse debt to assets ratio.
SPRY Yearly Shares OutstandingSPRY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
SPRY Yearly Total Debt VS Total AssetsSPRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • SPRY has an Altman-Z score of 0.39. This is a bad value and indicates that SPRY is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.39, SPRY is in the better half of the industry, outperforming 60.73% of the companies in the same industry.
  • A Debt/Equity ratio of 0.84 indicates that SPRY is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.84, SPRY is not doing good in the industry: 72.53% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z 0.39
ROIC/WACCN/A
WACC8.75%
SPRY Yearly LT Debt VS Equity VS FCFSPRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • SPRY has a Current Ratio of 7.28. This indicates that SPRY is financially healthy and has no problem in meeting its short term obligations.
  • SPRY's Current ratio of 7.28 is fine compared to the rest of the industry. SPRY outperforms 69.44% of its industry peers.
  • A Quick Ratio of 7.06 indicates that SPRY has no problem at all paying its short term obligations.
  • SPRY's Quick ratio of 7.06 is fine compared to the rest of the industry. SPRY outperforms 68.67% of its industry peers.
Industry RankSector Rank
Current Ratio 7.28
Quick Ratio 7.06
SPRY Yearly Current Assets VS Current LiabilitesSPRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SPRY Growth Analysis

3.1 Past

  • SPRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3600.00%.
  • Looking at the last year, SPRY shows a decrease in Revenue. The Revenue has decreased by -5.46% in the last year.
  • SPRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 299.68% yearly.
EPS 1Y (TTM)-3600%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-185.71%
Revenue 1Y (TTM)-5.46%
Revenue growth 3Y299.68%
Revenue growth 5YN/A
Sales Q2Q%-67.56%

3.2 Future

  • SPRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.68% yearly.
  • SPRY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.48% yearly.
EPS Next Y18.01%
EPS Next 2Y36.6%
EPS Next 3Y30.6%
EPS Next 5Y17.68%
Revenue Next Year111.43%
Revenue Next 2Y100.96%
Revenue Next 3Y80.78%
Revenue Next 5Y56.48%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SPRY Yearly Revenue VS EstimatesSPRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
SPRY Yearly EPS VS EstimatesSPRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. SPRY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SPRY. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRY Price Earnings VS Forward Price EarningsSPRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRY Per share dataSPRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

  • SPRY's earnings are expected to grow with 30.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.6%
EPS Next 3Y30.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SPRY Dividend Analysis

5.1 Amount

  • No dividends for SPRY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPRY Fundamentals: All Metrics, Ratios and Statistics

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (3/20/2026, 8:23:31 PM)

After market: 8.17 0 (0%)

8.17

-0.08 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-12
Inst Owners82.65%
Inst Owner ChangeN/A
Ins Owners11.86%
Ins Owner Change-1.69%
Market Cap811.28M
Revenue(TTM)84.28M
Net Income(TTM)-171.30M
Analysts88.33
Price Target28.73 (251.65%)
Short Float %31.03%
Short Ratio16.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.62%
Min EPS beat(2)-8.01%
Max EPS beat(2)6.77%
EPS beat(4)3
Avg EPS beat(4)0.96%
Min EPS beat(4)-8.01%
Max EPS beat(4)6.77%
EPS beat(8)5
Avg EPS beat(8)50.84%
EPS beat(12)8
Avg EPS beat(12)39.72%
EPS beat(16)9
Avg EPS beat(16)67.48%
Revenue beat(2)2
Avg Revenue beat(2)8.85%
Min Revenue beat(2)7.63%
Max Revenue beat(2)10.06%
Revenue beat(4)4
Avg Revenue beat(4)8.51%
Min Revenue beat(4)4.48%
Max Revenue beat(4)11.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.2%
EPS NQ rev (1m)-5.56%
EPS NQ rev (3m)-5.56%
EPS NY rev (1m)-6.16%
EPS NY rev (3m)-4.98%
Revenue NQ rev (1m)2.23%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)-3.88%
Revenue NY rev (3m)-5.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.63
P/FCF N/A
P/OCF N/A
P/B 7.1
P/tB 8.13
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.85
BVpS1.15
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.28%
ROE -149.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.77%
FCFM N/A
ROA(3y)-24.44%
ROA(5y)-22.49%
ROE(3y)-56.79%
ROE(5y)-42.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.8%
Cap/Sales 0.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.28
Quick Ratio 7.06
Altman-Z 0.39
F-Score2
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)325.73%
Cap/Depr(5y)243.07%
Cap/Sales(3y)194.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3600%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-185.71%
EPS Next Y18.01%
EPS Next 2Y36.6%
EPS Next 3Y30.6%
EPS Next 5Y17.68%
Revenue 1Y (TTM)-5.46%
Revenue growth 3Y299.68%
Revenue growth 5YN/A
Sales Q2Q%-67.56%
Revenue Next Year111.43%
Revenue Next 2Y100.96%
Revenue Next 3Y80.78%
Revenue Next 5Y56.48%
EBIT growth 1Y-5720.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1418.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1361.19%
OCF growth 3YN/A
OCF growth 5YN/A

ARS PHARMACEUTICALS INC / SPRY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ARS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SPRY.


Can you provide the valuation status for ARS PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to ARS PHARMACEUTICALS INC (SPRY). This can be considered as Overvalued.


Can you provide the profitability details for ARS PHARMACEUTICALS INC?

ARS PHARMACEUTICALS INC (SPRY) has a profitability rating of 1 / 10.